The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.
German pharma and life sciences major Merck KGaA today revealed it plans to invests more than 300 million euros ($32.7 million) into a new Bioprocessing Production Center in Daejeon, South Korea. 20 March 2024
Germany’s BioNTech has announced the appointment of Annemarie Hanekamp as the company’s new chief commercial officer, succeeding Sean Marett. 20 March 2024
German BioNTech stock fell nearly 9% to 85.72 euros in early trading today, as the company – which came into the limelight with the super successful COVID-19 vaccine Comirnaty partnered with Pfizer – as it posted financial results that disappointed. 20 March 2024
The US Food and Drug Administration (FDA) has granted accelerated approved the supplemental new drug application (sNDA) for Iclusig (ponatinib). 20 March 2024
Crinetics Pharmaceuticals, a biopharma focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, was trading 14% higher by lunchtime Tuesday. 19 March 2024
San-Diego Contineum Therapeutics, biotech developing small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications, is going public. 19 March 2024
Samsung Life Science Fund announced Samsung’s investment in Boston, USA-based BrickBio, a pre-clinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code. 19 March 2024
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house. 19 March 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024